Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexamethasone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 9/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.82 |
| ▸ | PGR | P06401 | 4/20 | 0.82 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.82 |
| ▸ | TSHR | P16473 | 2/20 | 0.82 |
| ▸ | AR | P10275 | 2/20 | 0.82 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.82 |
| ▸ | MEN1 | O00255 | 2/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.82 |
| ▸ | APEX1 | P27695 | 1/20 | 0.82 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.82 |
| ▸ | IKBKB | O14920 | 1/20 | 0.82 |
| ▸ | CHUK | O15111 | 1/20 | 0.82 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.82 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.82 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.82 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexamethasone SCHEMBL2940262 | 1.00 | NR3C1 (0.82) | NR3C1CYP3A4HIF1AHSD17B10PGR | |
| Dexamethasone SCHEMBL2933729 | 1.00 | NR3C1 (0.82) | NR3C1CYP3A4HIF1AHSD17B10PGR | |
| Betamethasone SCHEMBL29047992 | 1.00 | NR3C1 (0.82) | NR3C1CYP3A4HIF1AHSD17B10PGR | |
| Dexamethasone SCHEMBL2933295 | 1.00 | NR3C1 (0.82) | NR3C1CYP3A4HIF1AHSD17B10PGR | |
| Dexamethasone SCHEMBL25246105 | 1.00 | NR3C1 (0.82) | NR3C1CYP3A4HIF1AHSD17B10PGR | |
| Dexamethasone SCHEMBL25253296 | 1.00 | NR3C1 (0.82) | NR3C1CYP3A4HIF1AHSD17B10PGR | |
| Dexamethasone SCHEMBL25248831 | 1.00 | NR3C1 (0.82) | NR3C1CYP3A4HIF1AHSD17B10PGR | |
| Dexamethasone SCHEMBL25292805 | 1.00 | NR3C1 (0.82) | NR3C1CYP3A4HIF1AHSD17B10PGR | |
| Dexamethasone SCHEMBL5151472 | 1.00 | NR3C1 (0.82) | NR3C1CYP3A4HIF1AHSD17B10PGR | |
| Dexamethasone SCHEMBL25247721 | 0.99 | NR3C1 (0.83) | NR3C1CYP3A4HIF1AHSD17B10PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1914 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079802-A | Cationic lipids and compositions thereof | — | 2026-05-26 | — | — | CN | claimed |
| US-12611381-B2 | Cationic hyaluronic acid coated spanlastics and preparation and application thereof | FBC (SHANGHAI) PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2026-04-28 | — | — | US | claimed |
| US-20260108657-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OSTEOARTHRITIS | INSIGNIA PHARMACEUTICALS, LLC (US) | 2026-04-23 | — | — | US | claimed |
| EP-3253365-B1 | POLYAPHRONS AND PALPEBRAL ADMINISTRATION THEREOF | SANTEN PHARMACEUTICAL CO LTD (JP) | 2026-02-18 | — | — | EP | claimed |
| US-12491289-B2 | Pharmaceutical compositions for treating osteoarthritis | INSIGNIA PHARMACEUTICALS, LLC (US) | 2025-12-09 | — | — | US | claimed |
| EP-4654956-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OSTEOARTHRITIS | Insignia Pharmaceuticals, LLC (US) | 2025-12-03 | — | — | EP | claimed |
| US-20250352666-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | GENERATION BIO CO (US) | 2025-11-20 | — | — | US | claimed |
| EP-4626409-A1 | SYNTHETIC SINGLE STRANDED NUCLEIC ACID COMPOSITIONS AND METHODS THEREOF | Generation Bio Co. (US) | 2025-10-08 | — | — | EP | claimed |
| US-20250295608-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS | INSIGNIA PHARMACEUTICALS, LLC (US) | 2025-09-25 | — | — | US | claimed |
| US-20250288599-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS | INSIGNIA PHARMACEUTICALS, LLC (US) | 2025-09-18 | — | — | US | claimed |
| US-20070280995-A1 | Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye | NOVAGALI PHARMA SA (FR) | 2007-12-06 | — | — | US | claimed |
| WO-2007083316-A2 | MICROSPHERES COMPRISING NANOCAPSULES CONTAINING A LIPOPHILIC DRUG | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2007-07-26 | — | — | WO | claimed |
| WO-2003043602-A1 | SOLID DISPERSIONS CONTAINING SUBSTITUTED CYCLODEXTRIN AND INSOLUBLE DRUG AND THEIR PREPARATIONS | KOREA DDS PHARMACEUTICAL CO., LTD. (KR) | 2003-05-30 | — | — | WO | claimed |
| EP-1009409-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OCULAR INFLAMMATIONS COMPRISING DEXAMETHASONE PALMITATE | Pharmateam Development Ltd. (IL) | 2000-06-21 | — | — | EP | claimed |
| WO-1999011270-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OCULAR INFLAMMATIONS COMPRISING DEXAMETHASONE PALMITATE | PHARMATEAM DEVELOPMENT LTD. (IL) | 1999-03-11 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0041772-B2 | FAT EMULSION CONTAINING A STEROID | GREEN CROSS CORPORATION (JP) | 1990-04-18 | — | — | EP | claimed |
| EP-0041772-B1 | FAT EMULSION CONTAINING A STEROID | GREEN CROSS CORPORATION (JP) | 1984-10-17 | — | — | EP | claimed |
| US-4340594-A | Fat emulsion containing steroid | THE GREEN CROSS CORPORATION (JP) | 1982-07-20 | — | — | US | claimed |
| EP-0041772-A2 | Fat emulsion containing a steroid | GREEN CROSS CORPORATION (JP) | 1981-12-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12611381-B2 | Cationic hyaluronic acid coated spanlastics and preparation and application thereof | LIPA, CD44, HPSE | NR3C1 70/4885CYP3A4 1890/4885HIF1A 1869/4885 |
| US-20250352666-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | LIPA, EYA3, EYA2 | NR3C1 2356/4885CYP3A4 4870/4885HIF1A 814/4885 |
| US-20260108657-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OSTEOARTHRITIS | CD44, COL2A1, PPARD | NR3C1 29/4885CYP3A4 1665/4885HIF1A 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.